Mr. Rosty Raykov reports

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

The nominees listed in the management proxy circular dated April 24, 2023, for the annual general meeting of shareholders were elected as directors of Fennec Pharmaceuticals Inc. at the annual general meeting of shareholders held in New York on June 12, 2023.

Detailed results of the vote for the election of directors are set out in the attached table.

Shareholders voted 99.25 per cent in favour of appointing Haskell & White LLP as the auditor and authorizing the directors to fix the auditor remuneration, and 99.13 per cent in favour of the compensation paid to the company's named executive officers.

The company relied on the exemption set forth in Section 602.1 of the Toronto Stock Exchaneg company manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Stock Market, and accordingly did not seek shareholder reapproval for the unallocated shares under its long-term equity inventive plan at the annual general meeting this year.